These findings are consistent with the SOLAR-135 and BYLieve36 clinical trials, which demonstrated the benefit of alpelisib in hormone receptor-positive, HER2-negative breast cancer harboring PIK3CA mutations. This evidence concerns the gene PIK3CA and breast carcinoma.